drugset / Trial / NCT05305924
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2
Recruiting
28 enrolled
The Methodist Hospital Research Institute
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
Timeline
- Start
- 2021-02-25
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |